Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Clare Ling has been made an honorary Fellow of the Royal College of Pathologists (FRCPath). Currently running Shoklo Malaria Research Unit (SMRU) Microbiology department and supporting the unit’s molecular activities, Clare is a clinical scientist who has worked at SMRU on the Thai-Myanmar border since 2012.

Claire Ling wearing a lab coat in her office © 2020 MORU. Photographer: Gerhard Jørén.

News of Clare’s prestigious FRCPath award was enthusiastically received by colleagues.

“Congratulations to Clare on this richly deserved accolade. She is an extraordinarily talented scientist who has made a huge impact on microbiology at SMRU, benefitting both clinical science and the large population served by the SMRU clinics,” said Prof Nick Day, Director of the MORU Tropical Health Network. “Being awarded an honorary FRCPath is a rare occurrence, and reflects the esteem that Clare is held in by her colleagues in the MORU Network and around the world.”

“This is very good news (a rarity these days) and a very well-deserved recognition!” said SMRU Director Prof François Nosten. “Under Clare’s leadership, the microbiology lab has expanded, discovered new pathogens in the population, supported the TB program and become a key partner of the Thailand Ministry of Public Health in the fight against COVID-19.”

Since joining SMRU, Clare has particularly enjoyed the synergy between humanitarian and research activities. She is invested in improving the quality of the laboratory procedures for both research and diagnostic purposes at SMRU and leads the laboratory safety committee. In addition to providing Microbiology support across the research themes (TB, MCH and malaria elimination), Clare is particularly interested in respiratory infections with ongoing collaborative projects on Mycobacterium tuberculosis, M. amphoriforme, Ornithobacterium hominis and Streptococcus pneumoniae. Clare is also working with the Community Engagement team, FilmAid and colleagues at MORU to increase the awareness of Melioidosis on the Thailand-Myanmar border and to determine if it is a rare or undiagnosed infection in the region.

Following her honours degree in Medical Microbiology at Edinburgh University, Clare completed a three-year Clinical Scientist training programme at Raigmore Hospital Inverness. During this time, she obtained an MSc in Molecular Medical Microbiology at Nottingham University and carried out research on Borrelia burgdorferi, the aetiological agent of Lyme disease. She was a member of the team involved in the isolation of B. burgdorferi from ticks in the Highlands of Scotland, the first time this had been achieved. 

Clare then moved to the Royal Free Hospital NHS Trust, London (RFH) where she ran the molecular diagnostic service; undertook at PhD investigating a recently discovered Mycoplasma spp. Mycoplasma amphoriforme with University College London (UCL) and played an active role in the training of other scientists. Clare’s last post before joining SMRU was with Public Health England, where she pursued the development and implementation of molecular methods for gastrointestinal and respiratory infections. 

Similar stories

Are we getting tafenoquine dosing right?

Researchers analysing clinical trial data for the new antimalarial drug tafenoquine find that higher doses are needed to cure reliably vivax malaria infection.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

SMRU and BHF inaugurate new Admin Building

Today saw the long-awaited grand opening of the new Shoklo Malaria Research Unit (SMRU) / Borderland Health Foundation (BHF) Admin Building in Mae Ramat, Thailand, near the Thai-Myanmar border. And, boy was it worth the wait! Years in the planning, the very impressive new Admin Building looked absolutely stunning, the siting and architecture being universally admired by the many guests.

Study shows clear link between antibiotic treatment and acquisition of AMR bacteria in children

A study of the genetic diversity of Streptococcus pneumoniae, the bacterium responsible for hundreds of thousands of infant deaths each year, found that deep sequencing whole pneumococcal populations gave unsurpassed sensitivity for detecting multiple colonisations and was twice as effective at detecting invasive virulent strains of the bacteria as current best methods, say researchers in a study published in Nature Microbiology.

Three new full Oxford Professors from MORU

Three MORU Network staff awarded full professorship at the Nuffield Department of Medicine, University of Oxford.

INTERBIO-21st study findings could help predict infants at risk of obesity

Fetal abdomen growth and the mother’s blood fat metabolites very early in pregnancy influence a child’s weight, body fat, vision and neurodevelopment at 2 years of age